But there is very little data on how the drug works in humans
Experimental Eye Research, 159 , 147155
He talks about it because his clinical team has used it widely for joint, tendon, and gut issues, with no reported adverse events in their patient base
The phase 3 TRIUMPH-4 data showed these rates at 9 mg and 12 mg doses respectively: Nausea: 38.1% and 43.2% (vs 10.7% placebo) Diarrhea: 34.7% and 33.1% (vs 13.4% placebo) Constipation: 21.8% and 25.0% (vs 8.7% placebo) Vomiting: 20.4% and 20.9% (vs placebo) These numbers are higher than cagrilintide monotherapy across the board
Rare but Serious Adverse Effects Even though rare, serious side effects can happen
Additionally, it is important to consider the dosage and concentration of glutathione in the supplement